Progesterone Therapy Remains the Preferable Medication
Healthcare providers usually prefer progesterone therapy owing to its fast action, and better efficacy. Recommended for patients with a history of preterm birth, the medication does not require surgery or anesthesia. FMI underlines that the adoption of progesterone therapy would accent over US$ 1 Bn in 2025. However, this preventative medication is expected to falter in the near term due to its side effects - mood swings, headaches, and bloating. Healthcare providers are thus turning to other therapies such as corticosteroid therapy, and tocolytics therapy.
North America’s Market Continues to Lead the Pack
Capturing about half total market value, North America continues to engage stakeholders over the due course of time. Conducive regulatory environment and reimbursement policies are the major forces driving the preterm birth prevention and management market in the developed region.
Several organizations in the US are introducing initiatives to address the existing preterm birth scenario, and health inequities. Market players are also eyeing Asia for relevant value creation owing to increasing caseloads of preterm births coupled with cost-effective preterm birth prevention and management therapies.
Strategic Convening for Stronger Foothold
Market players are entering into strategic collaboration with various healthcare systems in order to create awareness regarding preterm births. For instance, Sera Prognostics, has collaborated with Christina Care Health System to launch a new preterm birth study with their preterm diagnostic test kit, PreTRM® that tests for IGFBP-1. Intermountain Health has collaborated with Christina Care Health System for two breakthrough preterm birth studies. As these partnerships gain momentum, incumbents are well placed to considerably enhance their business footprint.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
How Growth will Unfold
Shareholders continue to allocate their capitals to hospital pharmacies for distribution of preterm birth prevention and management drugs. Revenues generated through hospital pharmacies will boost over 2x during the foreseeable timeframe. Market players are also uncovering new revenue lines via retail and mail-order pharmacies, which collectively capture around a third of overall market stack. Despite this shift, the margin growth of hospital pharmacies would remain atop in the preterm birth prevention and management market.
FREQUENTLY ASKED QUESTIONS ABOUT PRETERM BIRTH PREVENTION AND MANAGEMENT MARKET
What are the factors contributing to growth of the preterm birth prevention and management market?
Growing focus on targeted therapies and standard of care, particularly in the area of preterm birth, is increasing the need for preterm birth prevention and management drugs. Progesterone therapy hold a notable share of the preterm birth prevention and management market. Adoption of preterm birth prevention and management drug in developing economies is anticipated to gain significant traction.
What are the promising strategies for large manufacturers and small local players contributing to growth of the preterm birth prevention and management market?
The higher fragmented nature of the market particularly with progesterone therapy and the availability of optional intervention hampers the profitability of the business. However, increasing awareness about preterm birth prevention and management and growing demand for cost-effective treatment options for preterm birth prevention have increased the revenue opportunities for global manufacturers.
Which country is growing at highest pace in preterm birth prevention and management market during the forecast period?
The Preterm Birth Prevention and Management market in India is expected to witness significant growth due to highest number of preterm births coupled with affordability of preterm birth prevention and management therapies in country.
What are the initiatives taken up by organization that can aid growth of the preterm birth prevention and management hampering market?
Initiatives take up by various regional and international organizations in order to address on-going preterm birth scenario, and health inequities, help various healthcare facilities in research, advocacy, education, and healthcare innovation and community engagement for preterm birth. Pointedly offering growth opportunities for preterm birth prevention and management market.
Which region is expected to offer lucrative growth opportunities for the preterm birth prevention and management market?
North America and South Asia, being highly mature markets with higher concentration of manufacturers and healthcare resources, are estimated to drive growth of the global preterm birth prevention and management market. Furthermore, East Asia and South Asia are expected to be lucrative regions, as majority of manufacturers of low cost preterm birth prevention and management are focusing to establish facilities in these regions.
How is the competition scenario in the preterm birth prevention and management market?
Manufacturers in the preterm birth prevention and management market such as Teva Pharmaceutical Industries Ltd., Pfizer Inc., Novartis AG, Sanofi S.A. are aiming on organic and inorganic business expansions strategies by entering into sales agreement, mergers, partnership, and production partnership with local contract manufactures from developing economies. While key players like AMAG Pharmaceuticals, Ferring Pharmaceuticals, are opting for development of product associated USPs to leverage brand identity.
PRETERM BIRTH PREVENTION AND MANAGEMENT MARKET TAXONOMY
The market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
- Progesterone Therapy
- Corticosteroid Therapy
- Tocolytics Therapy
- Antihypertensive Therapy
- Magnesium Sulfate Therapy
- Heparin Prophylaxis Therapy
- Low-Dose Aspirin Therapy
- Antibiotics Therapy
Route of Administration
- Prior Spontaneous PTB
- Short Cervix
- Chronic Hypertension
- Antiphospholipid Antibody Syndrome
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
- North America
- Latin America
- South Asia
- East Asia
- Middle East And Africa